The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2931-2939

  Kennedy, Jae ^a   Tien, Yu Yu ^a   Cohen, Lawrence J ^a,b   Sclar, David Alexander ^a,b   Liu, Darren ^a   Blodgett, Elizabeth G ^a   Engle, Josh ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington Institute for Mental Health Research and Training   (United States)

Author keywords

antipsychotics; atypical; first generation; hospitalization; schizophrenia; second generation; typical

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADL DISABILITY; ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BODY MASS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SMOKING; WALKING DIFFICULTY;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; COGNITION DISORDERS; DISABILITY EVALUATION; DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HEALTH CARE SURVEYS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MEDICARE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SMOKING; UNITED STATES; YOUNG ADULT;

EID: 74549214942     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.017     Document Type: Article

References (39)

1. Kane J.M. Pharmacologic treatment of schizophrenia. Biol Psychiatry 46 (1999) 1396-1408
2. Hansen T.E., Casey D.E., and Hoffman W.F. Neuroleptic intolerance. Schizophr Bull. 23 (1997) 567-582
3. Fenton W.S., Blyler C.R., and Heinssen R.K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull. 23 (1997) 637-651
4. Masand P.S., Roca M., Turner M.S., and Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Prim Care Companion J Clin Psychiatry 11 (2009) 147-154
5. Borison R.L. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 4 (1997) 255-271
6. Sankaranarayanan J., and Puumala S.E. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: National estimates and associated factors. Clin Ther. 29 (2007) 723-741
7. Dewa C.S., Remington G., Herrmann N., et al. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther. 24 (2002) 1466-1476
8. Rosenheck R.A., Leslie D.L., and Doshi J.A. Second-generation antipsychotics: Cost-effectiveness, policy options, and political decision making. Psychiatr Serv. 59 (2008) 515-520
9. Lieberman J.A., Stroup T.S., McEvoy J.P., et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353 (2005) 1209-1223
10. Kirshner H.S. Controversies in behavioral neurology: The use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Curr Neurol Neurosci Rep. 8 (2008) 471-474
11. Trifirò G., Spina E., and Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?. Pharmacol Res. 59 (2009) 1-12
12. Henderson D.C. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J Clin Psychiatry 69 (2008) e04
13. Baker R.A., Pikalov A., Tran Q.V., et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration adverse event database: A systematic bayesian signal detection analysis. Psychopharmacol Bull. 42 (2009) 11-31
14. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia [published correction appears in J Am Geriatr Soc. 2006;54:1479]. J Am Geriatr Soc. 54 (2006) 354-361
15. Ray W.A., Chung C.P., Murray K.T., et al. Atypical antipsychotic drugs and the risk of sudden cardiac death [published correction appears in N Engl J Med. 2009;361:1814]. N Engl J Med. 360 (2009) 225-235
16. Coley K.C., Carter C.S., DaPos S.V., et al. Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 60 (1999) 850-856
17. Rabinowitz J., Lichtenberg P., Kaplan Z., et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 158 (2001) 266-269
18. Mojtabai R., Lavelle J., Gibson P.J., and Bromet E.J. Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes. Schizophr Bull. 29 (2003) 519-530
19. Olfson M., Mechanic D., Boyer C.A., et al. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis. 187 (1999) 721-729
20. Conley R.R., Kelly D.L., Love R.C., and McMahon R.P. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15 (2003) 23-31
21. Herceg M., Jukić V., Vidović D., et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: Retrospective cohort study. Croat Med J. 49 (2008) 215-223
22. Lin C.H., Lin S.C., Chen M.C., and Wang S.Y. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. J Chin Med Assoc. 69 (2006) 264-269
23. Stargardt T., Weinbrenner S., Busse R., et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ. 11 (2008) 89-97
24. Patel N.C., Dorson P.G., Edwards N., et al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv. 53 (2002) 891-893
25. Burke J.P. Antibiotic resistance-squeezing the balloon?. JAMA 280 (1998) 1270-1271
26. O'Donnell B. Part D statistics. Presented at: 2009 Academy Health National Health Policy Conference. Washington, DC (February 2-3, 2009)
27. Barbui C., Cipriani A., and Tansella M. Conventional vs. atypical antipsychotic medications. N Engl J Med. 354 (2006) 972-974
28. Aparasu R.R., Jano E., Johnson M.L., and Chen H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother. 6 (2008) 198-204
29. Al-Zakwani I.S., Barron J.J., Bullano M.F., et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin. 19 (2003) 619-626
30. Simoni-Wastila L., Ryder P.T., Qian J., et al. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 17 (2009) 417-427
31. Schneeweiss S., Setoguchi S., Brookhart M.A., et al. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs. 23 (2009) 171-180
32. Adler G.S. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev. 15 (1994) 153-163
33. Eppig F.J., and Chulis G.S. Matching MCBS (Medicare Current Beneficiary Survey) and Medicare data: The best of both worlds. Health Care Financ Rev. 18 (1997) 211-219
34. Design and Estimation for the National Health Interview Survey, 1995-2004 (2000), US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Care Statistics, Hyattsville, Md
35. Hosmer D.W., Hosmer T., Le Cessie S., and Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 16 (1997) 965-980
36. Owens D.C. What CATIE did: Some thoughts on implications deep and wide. Psychiatr Serv. 59 (2008) 530-533
37. Leucht S., Corves C., Arbter D., et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373 (2009) 31-41
38. McCue R.E., Waheed R., Urcuyo L., et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 189 (2006) 433-440
39. Leucht S., Kissling W., and Davis J.M. Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?. Psychol Med. 39 (2009) 1591-1602